China Primary Hyperoxaluria (PH) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Primary hyperoxaluria (PH) is a group of rare genetic metabolic disorders that are characterized by the accumulation of a substance known as oxalate in the kidneys and other organ systems of the body. PH type I is the most common form. The global prevalence of PH type I is estimated to be 1-3 cases per 1,000,000 people. Globally PH1 accounts for 85% of patients, PH2 8-10% and PH3 5-7%. PH1 is the most severe form overall, more than 70% of PH1 patients develop end-stage kidney disease over time.
China is a growing market for primary hyperoxaluria (PH) due to factors such as increase in global prevalence rate (1-3 cases per 1,000,000 people). In addition to this, other factors that contribute to the growth of market are rise in healthcare expenditure, increase in awareness and increase in R&D activities by private players.
However, there are some restraining factors for growth of primary hyperoxaluria (PH) therapeutics market in China such as undiagnosed or misdiagnosed, determining the true frequency of these conditions in the general population is difficult.